Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinal Vessels | 9 | 2017 | 58 | 2.590 |
Why?
|
| Reperfusion Injury | 7 | 2011 | 131 | 2.060 |
Why?
|
| Retinal Diseases | 6 | 2016 | 90 | 1.940 |
Why?
|
| Ischemic Preconditioning | 7 | 2016 | 37 | 1.920 |
Why?
|
| Retina | 6 | 2016 | 213 | 1.330 |
Why?
|
| Ischemia | 5 | 2017 | 243 | 1.270 |
Why?
|
| Ischemic Postconditioning | 3 | 2011 | 10 | 1.170 |
Why?
|
| Electroretinography | 13 | 2018 | 76 | 0.970 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2011 | 125 | 0.760 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 3 | 2017 | 53 | 0.740 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2011 | 322 | 0.730 |
Why?
|
| Bone Marrow Cells | 3 | 2017 | 253 | 0.720 |
Why?
|
| Rats | 17 | 2018 | 3990 | 0.690 |
Why?
|
| Rats, Wistar | 6 | 2017 | 297 | 0.520 |
Why?
|
| Potassium Channels | 8 | 2009 | 340 | 0.500 |
Why?
|
| Dual Specificity Phosphatase 1 | 2 | 2011 | 17 | 0.490 |
Why?
|
| In Situ Nick-End Labeling | 6 | 2017 | 121 | 0.450 |
Why?
|
| Apoptosis | 9 | 2017 | 1683 | 0.420 |
Why?
|
| Blotting, Western | 5 | 2014 | 782 | 0.410 |
Why?
|
| Ventricular Function, Left | 3 | 2021 | 592 | 0.400 |
Why?
|
| Activins | 3 | 2021 | 26 | 0.400 |
Why?
|
| Mitogen-Activated Protein Kinase 14 | 1 | 2009 | 6 | 0.360 |
Why?
|
| Retinal Neurons | 1 | 2009 | 10 | 0.350 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2018 | 1219 | 0.350 |
Why?
|
| Receptors, Erythropoietin | 1 | 2009 | 14 | 0.350 |
Why?
|
| Erythropoietin | 1 | 2009 | 91 | 0.340 |
Why?
|
| Postpartum Period | 2 | 2021 | 135 | 0.340 |
Why?
|
| Protein Kinase C | 2 | 2008 | 270 | 0.320 |
Why?
|
| Potassium Channels, Calcium-Activated | 4 | 2002 | 19 | 0.310 |
Why?
|
| Pre-Eclampsia | 2 | 2021 | 246 | 0.310 |
Why?
|
| Animals | 20 | 2018 | 26581 | 0.300 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 4 | 2010 | 68 | 0.300 |
Why?
|
| Intraocular Pressure | 3 | 2011 | 54 | 0.280 |
Why?
|
| Disease Models, Animal | 5 | 2018 | 2232 | 0.280 |
Why?
|
| Diazoxide | 4 | 2009 | 19 | 0.280 |
Why?
|
| Zinc | 2 | 1997 | 91 | 0.260 |
Why?
|
| Calcium | 3 | 2000 | 1156 | 0.260 |
Why?
|
| Culture Media, Conditioned | 2 | 2016 | 104 | 0.260 |
Why?
|
| Heart Ventricles | 2 | 2021 | 760 | 0.250 |
Why?
|
| RNA, Small Interfering | 3 | 2011 | 547 | 0.230 |
Why?
|
| Retinal Ganglion Cells | 3 | 2016 | 66 | 0.220 |
Why?
|
| Time Factors | 5 | 2021 | 5209 | 0.210 |
Why?
|
| Potassium Channel Blockers | 2 | 2006 | 64 | 0.200 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2000 | 19 | 0.190 |
Why?
|
| Myocardial Contraction | 1 | 2021 | 244 | 0.180 |
Why?
|
| Prenatal Care | 1 | 2020 | 72 | 0.180 |
Why?
|
| Cells, Cultured | 5 | 2016 | 2818 | 0.180 |
Why?
|
| Anesthetics | 1 | 2000 | 48 | 0.180 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2010 | 115 | 0.180 |
Why?
|
| Blood Pressure | 2 | 2018 | 1143 | 0.180 |
Why?
|
| Aspirin | 1 | 2020 | 156 | 0.170 |
Why?
|
| Optic Nerve Injuries | 1 | 2018 | 3 | 0.170 |
Why?
|
| Head-Down Tilt | 1 | 2018 | 5 | 0.170 |
Why?
|
| Hemodilution | 1 | 2018 | 13 | 0.170 |
Why?
|
| RNA Interference | 2 | 2010 | 369 | 0.170 |
Why?
|
| Optic Neuropathy, Ischemic | 1 | 2018 | 19 | 0.160 |
Why?
|
| Oocytes | 2 | 2002 | 221 | 0.160 |
Why?
|
| Heart Diseases | 1 | 2021 | 290 | 0.160 |
Why?
|
| Receptors, Glutamate | 2 | 1997 | 24 | 0.160 |
Why?
|
| Intravitreal Injections | 2 | 2017 | 67 | 0.160 |
Why?
|
| Isoenzymes | 2 | 2008 | 271 | 0.150 |
Why?
|
| Retinal Degeneration | 1 | 2017 | 28 | 0.150 |
Why?
|
| Phosphorylation | 2 | 2010 | 1106 | 0.150 |
Why?
|
| Biomarkers | 4 | 2021 | 1718 | 0.150 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2018 | 69 | 0.150 |
Why?
|
| Receptors, AMPA | 1 | 1997 | 66 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2008 | 1961 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2018 | 318 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2009 | 589 | 0.130 |
Why?
|
| Kainic Acid | 1 | 1994 | 22 | 0.120 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2014 | 103 | 0.120 |
Why?
|
| Pyridines | 2 | 2009 | 309 | 0.120 |
Why?
|
| Brain | 2 | 2000 | 2216 | 0.110 |
Why?
|
| Flow Cytometry | 1 | 2014 | 679 | 0.110 |
Why?
|
| Patch-Clamp Techniques | 3 | 2002 | 396 | 0.100 |
Why?
|
| Tonometry, Ocular | 1 | 2011 | 10 | 0.100 |
Why?
|
| Neurons | 3 | 2009 | 1546 | 0.100 |
Why?
|
| Retinal Bipolar Cells | 1 | 2010 | 3 | 0.100 |
Why?
|
| Cytoprotection | 1 | 2011 | 47 | 0.100 |
Why?
|
| Hypoxia | 1 | 2016 | 641 | 0.100 |
Why?
|
| Cell Count | 1 | 2011 | 195 | 0.100 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2010 | 67 | 0.090 |
Why?
|
| Warm Ischemia | 1 | 2010 | 28 | 0.090 |
Why?
|
| Protein Isoforms | 1 | 2011 | 270 | 0.090 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 188 | 0.090 |
Why?
|
| Anisomycin | 1 | 2009 | 9 | 0.090 |
Why?
|
| Adenosine A1 Receptor Antagonists | 1 | 2009 | 4 | 0.090 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2009 | 8 | 0.090 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2009 | 15 | 0.090 |
Why?
|
| Enzyme Activators | 1 | 2009 | 14 | 0.090 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2009 | 13 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2011 | 272 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 154 | 0.090 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2009 | 11 | 0.090 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 4 | 2002 | 14 | 0.090 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2009 | 33 | 0.090 |
Why?
|
| Chlorpropamide | 1 | 2008 | 3 | 0.090 |
Why?
|
| Solubility | 1 | 2009 | 177 | 0.080 |
Why?
|
| Androstadienes | 1 | 2008 | 72 | 0.080 |
Why?
|
| Benzopyrans | 1 | 2008 | 20 | 0.080 |
Why?
|
| Imidazoles | 1 | 2009 | 162 | 0.080 |
Why?
|
| Acetophenones | 1 | 2008 | 27 | 0.080 |
Why?
|
| Pregnancy | 3 | 2021 | 2893 | 0.080 |
Why?
|
| Vasodilator Agents | 1 | 2008 | 152 | 0.080 |
Why?
|
| Recombinant Proteins | 4 | 2002 | 1014 | 0.070 |
Why?
|
| Membrane Potentials | 3 | 2002 | 435 | 0.070 |
Why?
|
| Xenopus laevis | 2 | 1997 | 137 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 639 | 0.060 |
Why?
|
| Echocardiography | 2 | 2021 | 911 | 0.060 |
Why?
|
| Riluzole | 1 | 2002 | 15 | 0.060 |
Why?
|
| Cell Line | 3 | 2002 | 2468 | 0.050 |
Why?
|
| Neuroprotective Agents | 1 | 2002 | 94 | 0.050 |
Why?
|
| Chlorzoxazone | 1 | 2001 | 5 | 0.050 |
Why?
|
| Muscle Relaxants, Central | 1 | 2001 | 10 | 0.050 |
Why?
|
| Male | 4 | 2018 | 40956 | 0.050 |
Why?
|
| Dequalinium | 1 | 2000 | 3 | 0.050 |
Why?
|
| Ion Channels | 1 | 2002 | 246 | 0.050 |
Why?
|
| DNA, Recombinant | 1 | 2000 | 67 | 0.050 |
Why?
|
| Follistatin-Related Proteins | 1 | 2020 | 6 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2020 | 4210 | 0.050 |
Why?
|
| Follistatin | 1 | 2020 | 7 | 0.050 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1999 | 49 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2009 | 3241 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 504 | 0.040 |
Why?
|
| Indoles | 1 | 2000 | 318 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 916 | 0.040 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2018 | 70 | 0.040 |
Why?
|
| Female | 5 | 2021 | 44507 | 0.040 |
Why?
|
| Blood-Retinal Barrier | 1 | 2017 | 4 | 0.040 |
Why?
|
| Isomerism | 1 | 1997 | 28 | 0.040 |
Why?
|
| Anions | 1 | 1997 | 31 | 0.040 |
Why?
|
| Sulfates | 1 | 1997 | 56 | 0.040 |
Why?
|
| Osmolar Concentration | 1 | 1997 | 181 | 0.040 |
Why?
|
| Culture Media | 1 | 1997 | 147 | 0.040 |
Why?
|
| DNA Damage | 1 | 1999 | 366 | 0.040 |
Why?
|
| Perioperative Care | 1 | 2018 | 161 | 0.040 |
Why?
|
| Injections, Intraocular | 1 | 2016 | 5 | 0.040 |
Why?
|
| Capillary Permeability | 1 | 2017 | 130 | 0.040 |
Why?
|
| Adult | 3 | 2021 | 25640 | 0.040 |
Why?
|
| Gene Expression | 1 | 2000 | 1284 | 0.030 |
Why?
|
| Humans | 7 | 2021 | 86601 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 3636 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1804 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1994 | 303 | 0.030 |
Why?
|
| Prognosis | 1 | 2021 | 3674 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1994 | 646 | 0.030 |
Why?
|
| Electrophysiology | 2 | 2002 | 401 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 5974 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2020 | 7988 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 8475 | 0.020 |
Why?
|
| Hydroxy Acids | 1 | 2006 | 9 | 0.020 |
Why?
|
| Nitroarginine | 1 | 2006 | 16 | 0.020 |
Why?
|
| Decanoic Acids | 1 | 2006 | 11 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2006 | 88 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2006 | 278 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2006 | 480 | 0.010 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2002 | 9 | 0.010 |
Why?
|
| Neural Conduction | 1 | 2002 | 69 | 0.010 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2002 | 45 | 0.010 |
Why?
|
| Mitochondria | 1 | 2006 | 535 | 0.010 |
Why?
|
| Xenopus | 1 | 2002 | 125 | 0.010 |
Why?
|
| Extracellular Space | 1 | 2002 | 90 | 0.010 |
Why?
|
| Magnesium | 1 | 2002 | 177 | 0.010 |
Why?
|
| Sodium Channels | 1 | 2002 | 129 | 0.010 |
Why?
|
| Zoxazolamine | 1 | 2001 | 2 | 0.010 |
Why?
|
| Calcium Channel Agonists | 1 | 2001 | 13 | 0.010 |
Why?
|
| Artifacts | 1 | 2002 | 244 | 0.010 |
Why?
|
| Mammals | 1 | 2002 | 227 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2001 | 408 | 0.010 |
Why?
|
| Benzimidazoles | 1 | 2001 | 140 | 0.010 |
Why?
|
| Ion Channel Gating | 1 | 2002 | 324 | 0.010 |
Why?
|
| Hippocampus | 1 | 2002 | 442 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 696 | 0.010 |
Why?
|
| DNA Repair | 1 | 1999 | 356 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 1999 | 584 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1999 | 2705 | 0.010 |
Why?
|